FibroGen Story Overview

FGEN -- USA Stock  

USD 63.88  1.07  1.65%

Macroaxis does not monitor all media channels or aggregates social signals for FibroGen. But even though we do not provide professional-grade financial sentiment analysis on FibroGen, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for FibroGen. Additionally see FibroGen Hype Analysis, FibroGen Correlation and FibroGen Performance.
Insider Selling FibroGen, Inc Director Sells 567000.00 in Stock
EcoR1 Capital LLC lifted its holdings in FibroGen by 3,674.1 percent in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company stock valued at 51,210,000 after acquiring an additional 1,543,448 shares during the ... Traders Brace for Comeback of Volatility FibroGen, Inc. , Frontline Ltd ... - Post Analyst

Read More...   

Story Momentum

This media report from www.thelincolnianonline.com distributed on December 7, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 2.54% . The overall trading delta when the story was published against the current closing price is 42.21% .

Similar stores for FibroGen

a day ago at http://kldaily.com 
FibroGen, Inc. Stock Price Hits 52-Week High Today
news
KL DailyWhat PE Ratio is Telling To Potential Investors FibroGen Inc Stocks Market CapFibroGen Inc Director Roberto Pedro Rosenkranz Sells 1000 Shares registrarjournal.comFibroGen to Present at Two Upcoming Investor Conferences GlobeNewswireFull coverage
few days ago at http://www.thecoinguild.com 
Making Headlines Investors Zeroing in on FibroGen, Inc
news
The Coin GuildFull coverage
over a week ago at www.macroaxis.com 
Exercise or conversion by Pat Cotroneo of 7750 shares of FibroGen subject to Rule 16b-3
Macroaxis News
Filed transaction by Fibrogen Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a week ago at http://ledgergazette.com 
American Century Companies Inc. Purchases 1294 Shares of FibroGen
news
The Ledger GazetteFibroGen Upgraded to Buy by ValuEngine registrarjournal.comFibroGen Earns Buy Rating from Mizuho The Lincolnian OnlineFull coverage
over two weeks ago at http://www.nasdaqfortune.com 
Acquisition by Gerald Lema of 6000 shares of FibroGen subject to Rule 16b-3
nasdaq News
Filed transaction by Fibrogen Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at http://markets.businessinsider.com 
FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable ...
businessinsider News
Markets InsiderFull coverage
over three weeks ago at http://www.derbynewsjournal.com 
What Can FibroGen, Inc. s Quant Signals Tell Us About the Shares
wsj  News
Derby JournalFull coverage
over three weeks ago at www.macroaxis.com 
FibroGen exotic insider transaction detected
Macroaxis News
Filed transaction by Fibrogen Inc director. Unconventional Insider trading
over a month ago at http://arcadiacaller.com 
Tracking the Opinion Signal For Fibrogen Inc CS
news
The CallerFull coverage
over a month ago at www.macroaxis.com 
Exercise or conversion by Thomas Neff of 10320 shares of FibroGen subject to Rule 16b-3
Macroaxis News
Filed transaction by Fibrogen Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at http://globenewswire.com 
Exercise or conversion by Jorma Routti of 6000 shares of FibroGen subject to Rule 16b-3
news
Filed transaction by Fibrogen Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two months ago at http://newburghgazette.com 
Crown Castle International Stock Rating Lowered by Goldman Sachs
news
Newburgh GazetteSpinnaker Trust Increased Crown Castle International Stake 5 Analysts Bullish FibroGen, Inc. FlintDaily.comFull coverage
over three months ago at http://thewellesleysnews.com 
Exercise or conversion by Thomas Neff of 10265 shares of FibroGen subject to Rule 16b-3
news
Filed transaction by Fibrogen Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Did you try this?

Run Efficient Frontier Now
   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Efficient Frontier

Cash and Equivalents

Cash and Equivalents Comparative Analysis
  Cash and Equivalents 
      FibroGen Comparables 
FibroGen is currently under evaluation in cash and equivalents category among related companies. Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Peers

FibroGen Related Equities
DMPI  16.46 %   
0%
100.0%
VBLT  10.00 %   
0%
60.0%
VCEL  6.36 %   
0%
38.0%
VBIV  5.28 %   
0%
32.0%
DRRX  5.13 %   
0%
31.0%
DMTX  0.00 %   
0%
0%
DNLI  0.95 %   
5.0%
0%
DOVA  4.71 %   
28.0%
0%
NK  6.83 %   
41.0%
0%
DRNA  7.69 %   
46.0%
0%
Additionally see FibroGen Hype Analysis, FibroGen Correlation and FibroGen Performance. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.